Sort
4,870 grants matching “glp 1”
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease
$1,079,215Jay Williams Hooper · Geneva Foundation · R01 · FY2019 · AI
Project 5: IND-enabling Critical Path Project: GMP Manufacture of a Combination I
$1,078,750Amanda Malone · Oak Crest Institute Of Science · U19 · FY2018 · AI
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells
$1,078,081Scott McNear Thacher · Orphagen Pharmaceuticals · R44 · FY2024 · DK
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.
$1,077,584Jaipal Singh · Vasculonics, Llc · R44 · FY2024 · HL
Title: Developing a novel drug for neurobehavioral deficits in FASD
$1,077,312Masaaki Torii · Cogthera, Llc · R42 · FY2025 · AA
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections
$1,076,832David S Perlin · Hackensack University Medical Center · R01 · FY2022 · AI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
$1,076,832David S Perlin · Hackensack University Medical Center · R01 · FY2021 · AI
Retinal Gene Therapy
$1,071,862Peter Colosi · National Eye Institute · ZIA · FY2009 · EY
Biomechatronics Device for Diagnosis/Therapy of Anorectal Disorders
$1,070,822William Combs · 3dt Holdings, Llc · R44 · FY2022 · DK
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
$1,070,621David S Perlin · Hackensack University Medical Center · R01 · FY2019 · AI
Orally-Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post-Surgical Pain
$1,070,335Scott L Dax · Cersci Therapeutics, Inc. · R44 · FY2018 · DA
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases
$1,069,999Jeremy Blitzer · Potrero Hill Therapeutics, Inc. · R44 · FY2022 · DK
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases
$1,069,999Jeremy Blitzer · Potrero Hill Therapeutics, Inc. · R44 · FY2021 · DK
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases
$1,069,999Jeremy Blitzer · Potrero Hill Therapeutics, Inc. · R44 · FY2020 · DK
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,069,709Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2008 · AI
Development of an anti-malaria toxin vaccine candidate
$1,067,392William J Christ · Ancora Pharmaceuticals, Inc. · R44 · FY2006 · AI
Neuroprotective Apolipoprotein-E Analogs Continuation
$1,066,881Michael Peter Vitek · Cognosci, Inc. · R44 · FY2008 · AG
Development of an anti-malaria toxin vaccine candidate
$1,066,844Ancora Pharmaceuticals, Inc. · R44 · FY2005 · AI
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation
$1,066,178Dianna Ammons Johnson · Tavo Biotherapeutics, Inc · R44 · FY2024 · EY
Software-guided Operative Planning of MitraClip Placement
$1,065,759Julius Matteo Guccione · 3dt Holdings, Llc · R44 · FY2025 · HL
Theranostic for gastric cancer
$1,065,500Valerie Humblet · Collagen Medical, Llc · R44 · FY2025 · CA
Cannabinoid CB1 and CB2 receptors and drug abuse
$1,064,560Zheng-Xiong Xi · National Institute On Drug Abuse · ZIA · FY2025 · DA
Development of JS-K as an anti-leukemic agent
$1,063,969Paul J Shami · University Of Utah · R01 · FY2009 · CA
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
$1,062,913Cathy A Swindlehurst · Novomedix, Inc. · R44 · FY2022 · HL
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
$1,062,082Craig Patrick Ramirez · Tezcat Laboratories Llc · R44 · FY2023 · CA